Crossref
BCMA-directed antibodies in multiple myeloma: new agents and treatment strategies from IMS 2026
Clinical Lymphoma Myeloma and Leukemia · 2026-10
DOI: 10.1016/j.clml.2026.10.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Yuping Si und 2 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben. Gefördert von: Beijing Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Beijing Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Si, Y., Li, C., & Hou, L. (2026). BCMA-directed antibodies in multiple myeloma: new agents and treatment strategies from IMS 2026. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.10.024
Vancouver
Si Y, Li C, Hou L. BCMA-directed antibodies in multiple myeloma: new agents and treatment strategies from IMS 2026. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.10.024
BibTeX
@article{Si2026,
author = {Si, Yuping and Li, Changnian and Hou, Li},
title = {BCMA-directed antibodies in multiple myeloma: new agents and treatment strategies from IMS 2026},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2026.10.024}
}
EUVIMED